Tumor Necrosis Factor-α Gene Polymorphism is Associated with Short- and Long-Term Kidney Allograft Outcomes

References

• Wekerle T, Segev D, Lechler R, Oberbauer R. Strategies for long-term preservation of kidney graft function. Lancet. 2017;389(10084):2152–2162. doi:10.1016/S0140-673617
   PubMed Web of Science ®Google Scholar
• Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov. 2016;15(8):568–588. doi:10.1038/nrd.2016.67
   PubMed Web of Science ®Google Scholar
• Stegall MD, Troy Somerville K, Everly MJ, et al. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: the Transplant Therapeutics Consortium’s position statement. Am J Transplant. 2019;19(3):625–632. doi:10.1111/ajt.15214
   PubMed Web of Science ®Google Scholar
• Edmonston DL, Roe MT, Block G, et al. Drug Development in Kidney Disease: proceedings From a Multistakeholder Conference. Am J Kidney Dis. 2020;76(6):842–850. doi:10.1053/J.AJKD.2020.05.026
   PubMed Web of Science ®Google Scholar
• Rudrapal M, Khairnar S J, Jadhav A G. Drug Repurposing (DR): an emerging approach in drug discovery. In: Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen; 2020. doi10.5772/intechopen.93193
   Google Scholar
• Holdsworth SR, Can PY. Cytokines: names and numbers you should care about. Clin J Am Soc Nephrol. 2015;10(12):2243–2254. doi:10.2215/CJN.07590714
   PubMed Web of Science ®Google Scholar
• Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15(6):362–374. doi:10.1038/nri3834
   PubMed Web of Science ®Google Scholar
• Lim H, Lee SH, Lee HT, et al. Structural biology of the TNFα antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. 2018;19(3):768. doi:10.3390/ijms19030768
   PubMed Web of Science ®Google Scholar
• Jang D, Lee A-H, Shin H-Y, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):1–16. doi:10.3390/IJMS22052719
   Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62. doi:10.1038/nrrheum.2015.169
   PubMed Web of Science ®Google Scholar
• Feldmann M, Pusey CD. Is there a role for TNF-α in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol. 2006;17(5):1243–1252. doi:10.1681/ASN.2005121359
   PubMed Web of Science ®Google Scholar
• Nagata Y, Fujimoto M, Nakamura K, et al. Anti-TNF-α agent infliximab and splenectomy are protective against renal ischemia-reperfusion injury. Transplantation. 2016;100(8):1675–1682. doi:10.1097/TP.0000000000001222
   PubMed Web of Science ®Google Scholar
• Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E. The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-αR1: a comparison with infliximab treatment. Eur J Pharmacol. 2013;700(1–3):134–146. doi:10.1016/j.ejphar.2012.11.066
   PubMed Web of Science ®Google Scholar
• Tasdemir C, Tasdemir S, Vardi N, et al. Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney. Ren Fail. 2012;34(9):1144–1149. doi:10.3109/0886022X.2012.717490
   PubMed Web of Science ®Google Scholar
• Moers C, Pol RA, De Borst MH. Tumor necrosis factor a blockade to ameliorate renal ischemia reperfusion injury: potential implications for kidney transplantation. Transplantation. 2016;100(8):1601–1602. doi:10.1097/TP.0000000000001221
   PubMed Web of Science ®Google Scholar
• King EA, Wade DJ, Degner JF, Marchini J. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15(12):e1008489. doi:10.1371/journal.pgen.1008489
   PubMed Web of Science ®Google Scholar
• Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856–860. doi:10.1038/ng.3314
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhan L, Zhu Y, Sun H, Xu X. Tumor necrosis factor alpha gene polymorphisms increase susceptibility to adenovirus infection in children and are correlated with severity of adenovirus-associated pneumonia. Genet Test Mol Biomarkers. 2020;24(12):761–770. doi:10.1089/gtmb.2020.0122
   PubMed Web of Science ®Google Scholar
• Khan S, Mandal RK, Jawed A, et al. TNF-α −308 G > A (rs1800629) polymorphism is associated with celiac disease: a meta-analysis of 11 case-control studies. Sci Rep. 2016;6(1):1–10. doi:10.1038/srep32677
   PubMed Web of Science ®Google Scholar
• Dessing MC, Kers J, Damman J, Navis GJ, Florquin S, Leemans JC. Donor and recipient genetic variants in NLRP3 associate with early acute rejection following kidney transplantation. Sci Rep. 2016;6. doi:10.1038/srep36315
   Web of Science ®Google Scholar
• Damman J, Daha MR, Leuvenink HG, et al. Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am J Transplant. 2012;12(3):660–668. doi:10.1111/j.1600-6143.2011.03880.x
   PubMed Web of Science ®Google Scholar
• Damman J, Kok JL, Snieder H, et al. Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation. Mol Immunol. 2012;50(1–2):1–8. doi:10.1016/j.molimm.2011.11.009
   PubMed Web of Science ®Google Scholar
• Poppelaars F, Gaya Da Costa M, Eskandari SK, Damman J, Seelen MA. Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation. medRxiv. 2021;11:1–4. doi:10.1101/2021.04.17.21255669
   Google Scholar
• Poppelaars F, Gaya da Costa M, Faria B, Eskandari SK, Damman J, Seelen MA. A functional TGFB1 polymorphism in the donor associates with long-term graft survival after kidney transplantation. Clin Kidney J. 2021;15:278–286. doi:10.1093/ckj/sfab175
   PubMed Web of Science ®Google Scholar
• Chen G, Liu B, Li H, et al. Ethnicity-stratified analysis of the association between TNF- α genetic polymorphisms and acute kidney injury: a systematic review and meta-analysis. Biomed Res Int. 2020;2020. doi:10.1155/2020/5262351
   Web of Science ®Google Scholar
• Israni AK, Li N, Cizman BB, et al. Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function After kidney transplantation. Am J Kidney Dis. 2008;52(2):331–339. doi:10.1053/j.ajkd.2008.05.006
   PubMed Web of Science ®Google Scholar
• Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature15393
   PubMed Web of Science ®Google Scholar
• Tang R, Sinnwell JP, Li J, Rider DN, de Andrade M, Biernacka JM. Identification of genes and haplotypes that predict rheumatoid arthritis using random forests. BMC Proc. 2009;3(Suppl 7):S68. doi:10.1186/1753-6561-3-s7-s68
   PubMedGoogle Scholar
• Kühl T, Behrens S, Jung AY, et al. Validation of inflammatory genetic variants associated with long-term cancer related fatigue in a large breast cancer cohort. Brain Behav Immun. 2018;73:252–260. doi:10.1016/j.bbi.2018.05.009
   PubMed Web of Science ®Google Scholar
• van Meeteren MJW, Hayee B, Inderson A, et al. Safety of anti-TNF treatment in liver transplant recipients: a systematic review and metaanalysis. J Crohn’s Colitis. 2017;11(9):1146–1151. doi:10.1093/ecco-jcc/jjx057
   Google Scholar
• Quinn CS, Jorgenson MR, Descourouez JL, Muth BL, Astor BC, Mandelbrot DA. Management of tumor necrosis factor α inhibitor therapy after renal transplantation: a comparative analysis and associated outcomes. Ann Pharmacother. 2019;53(3):268–275. doi:10.1177/1060028018802814
   PubMed Web of Science ®Google Scholar
• Diuwe P, Domagala P, Durlik M, Trzebicki J, Chmura A, Kwiatkowski A. The effect of the use of a TNF-alpha inhibitor in hypothermic machine perfusion on kidney function after transplantation. Contemp Clin Trials. 2017;59:44–50. doi:10.1016/j.cct.2017.05.013
   PubMed Web of Science ®Google Scholar
• Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: local tumor necrosis factor-α inhibition in inflammatory bowel disease. Pharmaceutics. 2020;12(6):1–31. doi:10.3390/pharmaceutics12060539
   Web of Science ®Google Scholar
• de Vries DK, Wijermars LGM, Reinders MEJ, Lindeman JHN, Schaapherder AFM. Donor pre-treatment in clinical kidney transplantation: a critical appraisal. Clin Transplant. 2013;27(6):799–808. doi:10.1111/ctr.12261
   PubMed Web of Science ®Google Scholar
• O’Neill S, Oniscu GC. Donor pretreatment and machine perfusion: current views. Curr Opin Organ Transplant. 2020;25(1):59–65. doi:10.1097/MOT.0000000000000725
   PubMed Web of Science ®Google Scholar